[go: up one dir, main page]

MX2021000515A - Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. - Google Patents

Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Info

Publication number
MX2021000515A
MX2021000515A MX2021000515A MX2021000515A MX2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A
Authority
MX
Mexico
Prior art keywords
disease
treat alzheimer
riluzole
riluzole prodrugs
prodrugs
Prior art date
Application number
MX2021000515A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Irfan Qureshi
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2021000515A publication Critical patent/MX2021000515A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar la enfermedad de Alzheimer al administrar a un paciente en necesidad de esto un profármaco de riluzol tal como troriluzol. También se describen composiciones farmacéuticas y kits que incluyen profármacos de riluzol.
MX2021000515A 2018-07-22 2019-07-20 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. MX2021000515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2021000515A true MX2021000515A (es) 2021-06-08

Family

ID=69181140

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000515A MX2021000515A (es) 2018-07-22 2019-07-20 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX2024010655A MX2024010655A (es) 2018-07-22 2021-01-14 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010655A MX2024010655A (es) 2018-07-22 2021-01-14 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Country Status (14)

Country Link
US (1) US12161633B2 (es)
EP (1) EP3823616A4 (es)
JP (2) JP2021530543A (es)
KR (1) KR20210034621A (es)
CN (1) CN112469408A (es)
AU (1) AU2019310013B2 (es)
BR (1) BR112021000768A2 (es)
CA (1) CA3107215A1 (es)
EA (1) EA202190308A1 (es)
IL (1) IL280177B2 (es)
MX (2) MX2021000515A (es)
PH (1) PH12021550043A1 (es)
SG (1) SG11202100385YA (es)
WO (1) WO2020023324A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187323A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
CA3193824A1 (en) * 2020-10-05 2022-04-14 Ana PEREIRA Riluzole for the treatment of alzheimer's disease
US20240082340A1 (en) * 2021-01-18 2024-03-14 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
EP4294384A4 (en) * 2021-02-22 2025-06-25 Yale University TARGETED BIFUNCTIONAL DEGRADING AGENTS
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000263A2 (en) * 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
FR2957077B1 (fr) 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
EP3223815B1 (en) * 2014-11-26 2021-07-28 MediciNova, Inc. Combination of ibudilast and riluzole and methods of using same
SG10201908354VA (en) * 2015-03-03 2019-10-30 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
RS65474B1 (sr) * 2016-05-20 2024-05-31 Biohaven Therapeutics Ltd Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents

Also Published As

Publication number Publication date
EP3823616A4 (en) 2022-05-04
MX2024010655A (es) 2024-09-11
KR20210034621A (ko) 2021-03-30
WO2020023324A1 (en) 2020-01-30
IL280177B2 (en) 2025-01-01
US12161633B2 (en) 2024-12-10
US20210290599A1 (en) 2021-09-23
IL280177B1 (en) 2024-09-01
IL280177A (en) 2021-03-01
JP2025093952A (ja) 2025-06-24
SG11202100385YA (en) 2021-02-25
CN112469408A (zh) 2021-03-09
PH12021550043A1 (en) 2021-09-20
AU2019310013A1 (en) 2021-02-11
AU2019310013B2 (en) 2025-01-02
EA202190308A1 (ru) 2021-05-19
EP3823616A1 (en) 2021-05-26
CA3107215A1 (en) 2020-01-30
BR112021000768A2 (pt) 2021-05-11
JP2021530543A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
NZ777871A (en) Small molecule modulators of il-17
PH12018502634A1 (en) Topical compositions of apremilast
ZA202002626B (en) Use of riluzole prodrugs to treat ataxias
EP4306524A3 (en) Lymphatic system-directing lipid prodrugs
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12021550443A1 (en) Pyridazinones and methods of use thereof
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
JOP20190191A1 (ar) وحدات شجرية علاجية
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2016008968A (es) Compuestos organicos.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.